Dr. Jason W. Denbo is an Assistant Member in the Department of Gastrointestinal Oncology. Dr. Denbo earned his MD degree at Indiana University School of Medicine and completed a General Surgery Residency at the University of Tennessee Health Science Center and a Research Fellowship at St. Jude Children’s Research Hospital in Memphis, TN. Dr. Denbo received fellowship training in both Complex General Surgical Oncology and Advanced Hepatopancreatobiliary Surgery at MD Anderson Cancer Center. Prior to his recruitment to Moffitt, Dr. Denbo served as an Assistant Professor in the Department of Surgery at the University of Minnesota. Dr. Denbo’s clinical interests include primary and metastatic hepatobiliary tumors as well as primary pancreatic tumors with a specific focus on minimally invasive surgical procedures and adjunctive therapies. Dr. Denbo is the Founder and Director of the Robotic Hepatobiliary Program at Moffit. He also holds a Certification in Medical Quality from the American Board of Medical Quality and serves as the Assistant Chair of Surgical Safety. Dr. Denbo’s research interests include: 1) the impact of minimally invasive surgical procedures, the resultant inflammatory and immune response, on oncologic outcomes and receipt of intended multimodal therapy; 2) clinical trial design and implementation for resectable oncologically high-risk cholangiocarcinoma; 3) the role of patient factors and treatment sequencing strategies to maximize completion of intended therapy in resectable pancreatic cancer and clinical trial design for this cohort of patients. Dr. Denbo is extremely grateful for the education, training and mentorship he received throughout his many years surgical training and has a real passion for education of the next generation of surgical oncologists.
Gholami S, Perry LM, Denbo JW, Chavin K, Newell P, Ly Q, St Hill C, Morris-Stiff G, Kessler J, Frankel TL, Parikh ND, Philips P, Salti G, Augustin T, Aucejo F, Debroy M, Coburn N, Warner SG. Management of early hepatocellular carcinoma: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford). 2021 May.23(5):753-761. Pubmedid: 33008733.
Denbo JW, Kim BJ, Vauthey JN, Tzeng CW, Ma J, Huang SY, Chun YS, Katz MHG, Aloia TA. Overall Body Composition and Sarcopenia Are Associated with Poor Liver Hypertrophy Following Portal Vein Embolization. J Gastrointest Surg. 2021 Feb.25(2):405-410. Pubmedid: 31997073.
Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, Arnoletti JP, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33671939. Pmcid: PMC7919015.
Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol. 2021 Apr.28(4):1939-1949. Pubmedid: 33415559.
Denbo JW, Kim R, Anaya DA. ASO Author Reflections: Evolving Treatment Paradigms for High-Risk Intrahepatic Cholangiocarcinoma: What Does The Future Hold?. Ann Surg Oncol. 2021 Apr. Pubmedid: 33891197.
Denbo J, Anaya DA. Textbook Outcomes Following Liver Resection for Cancer: A New Standard for Quality Benchmarking and Patient Decision Making. Ann Surg Oncol. 2020 Sep.27(9):3118-3120. Pubmedid: 32385768.
Sheka AC, Altman A, Marmor S, Hui JYC, Denbo JW, Ankeny JS, Jensen EH. Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States. Surg Oncol. 2020 Sep.34:298-303. Pubmedid: 32891346.
Altman AM, Sheka AC, Marmor S, Lou E, Reynolds M, Hui JYC, Tuttle TM, Jensen EH, Denbo JW. The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer. Surg Oncol. 2020 Sep.34:134-139. Pubmedid: 32891318.
Denbo JW, Marmor S, Jensen EH. Correction to: Minimally Invasive Lymphadenectomy for Biliary Tumors: Stepwise Progress. Ann Surg Oncol. 2019 Dec.26(Suppl 3):885. Pubmedid: 30968253.
Marmor S, Altman AM, Mayleben WT, Hui JYC, Denbo JW, Jensen EH, Tuttle TM. The use of contralateral prophylactic mastectomy among elderly patients in the United States. Breast Cancer Res Treat. 2019 Aug.177(1):175-183. Pubmedid: 31140081.
Denbo JW, Bruno M, Dewhurst W, Kim MP, Tzeng CW, Aloia TA, Soliz J, Speer BB, Lee JE, Katz MHG. Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. Surgery. 2018 Sep.164(3):424-431. Pubmedid: 29807648. Pmcid: PMC7265789.
Altman AM, Kizy S, Marmor S, Huang JL, Denbo JW, Jensen EH. Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States. J Gastrointest Oncol. 2018 Oct.9(5):942-952. Pubmedid: 30505597. Pmcid: PMC6219978.
Altman AM, Kizy S, Yuan J, Denbo JW, Jensen EH, Hui JYC, Tuttle TM, Marmor S. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States. Ann Surg Oncol. 2018 Aug.25(8):2296-2302. Pubmedid: 29907942.
Cloyd JM, Nogueras-González GM, Prakash LR, Petzel MQB, Parker NH, Ngo-Huang AT, Fogelman D, Denbo JW, Garg N, Kim MP, Lee JE, Tzeng CD, Fleming JB, Katz MHG. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. J Gastrointest Surg. 2018 Apr.22(4):703-712. Pubmedid: 29230694. Pmcid: PMC6022283.
Weatherall T, Denbo J, Sharpe J, Martin M, O'Brien T, Gupta R, Groshart K, Behrman S, Dickson P. Well-Differentiated, Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors: Toward Defining Evaluation and Management. World J Surg. 2017 Mar.41(3):844-850. Pubmedid: 27743074.
Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul.24(7):2031-2039. Pubmedid: 28124275.
Tran Cao HS, Phuoc V, Ismael H, Denbo JW, Passot G, Yamashita S, Conrad C, Aloia TA, Vauthey JN. Rate of Organ Space Infection Is Reduced with the Use of an Air Leak Test During Major Hepatectomies. J Gastrointest Surg. 2017 Jan.21(1):85-93. Pubmedid: 27496092.
Denbo JW, Yamashita S, Passot G, Egger M, Chun YS, Kopetz SE, Maru D, Brudvik KW, Wei SH, Conrad C, Vauthey JN, Aloia TA. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Jan.21(1):68-77. Pubmedid: 27334313.
Cloyd JM, Tran Cao HS, Petzel MQ, Denbo JW, Parker NH, Nogueras-González GM, Liles JS, Kim MP, Lee JE, Vauthey JN, Aloia TA, Fleming JB, Katz MH. Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. J Surg Oncol. 2017 Feb.115(2):144-150. Pubmedid: 27859270.
Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017 Feb.161(2):332-340. Pubmedid: 27592215.
Ismael HN, Denbo J, Cox S, Crane CH, Das P, Krishnan S, Schroff RT, Javle M, Conrad C, Vauthey J, Aloia T. Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. Eur J Surg Oncol. 2016 Oct.42(10):1591-1596. Pubmedid: 27296729.
Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 Dec.20(12):1975-1985. Pubmedid: 27730398.
Denbo JW, Fleming JB. Definition and Management of Borderline Resectable Pancreatic Cancer. Surg Clin N Am. 2016 Dec.96(6):1337-1350. Pubmedid: 27865281.
Denbo JW, Zhu L, Srivastava D, Stokes DC, Srinivasan S, Hudson MM, Ness KK, Robison LL, Neel M, Rao B, Navid F, Davidoff AM, Green DM. Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. J Am Coll Surg. 2014 Aug.219(2):265-271. Pubmedid: 24795268. Pmcid: PMC4308956.
Orr WS, Denbo JW, Saab KR, Ng CY, Wu J, Li K, Garner JM, Morton CL, Du Z, Pfeffer LM, Davidoff AM. Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-κB activity. PLoS One. 2013 Sep.8(2):e51309. Pubmedid: 23408929. Pmcid: PMC3567084.
Denbo JW, Orr WS, Zarzaur BL, Behrman SW. Toward defining grade C pancreatic fistula following pancreaticoduodenectomy: incidence, risk factors, management and outcome. HPB (Oxford). 2012 Sep.14(9):589-593. Pubmedid: 22882195. Pmcid: PMC3461384.
Denbo JW, Shannon Orr W, Wu Y, Wu J, Billups CA, Navid F, Rao BN, Davidoff AM, Krasin MJ. Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol. 2012 Nov.19(12):3809-3815. Pubmedid: 22752372. Pmcid: PMC3529468.
Orr WS, Shannon Orr W, Denbo JW, Billups CA, Wu J, Navid F, Rao BN, Davidoff AM, Krasin MJ. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol. 2012 Nov.19(12):3816-3822. Pubmedid: 22739653.
Myers AL, Orr WS, Denbo JW, Ng CY, Zhou J, Spence Y, Wu J, Davidoff AM. Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 2012 Jan.47(1):183-189. Pubmedid: 22244414. Pmcid: PMC3259455.
Denbo JW, Williams RF, Orr WS, Sims TL, Ng CY, Zhou J, Spence Y, Morton CL, Nathwani AC, Duntsch C, Pfeffer LM, Davidoff AM. Continuous local delivery of interferon-β stabilizes tumor vasculature in an orthotopic glioblastoma xenograft resection model. Surgery. 2011 Sep.150(3):497-504. Pubmedid: 21878236. Pmcid: PMC3164960.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub